BackAvidity Biosciences Overview

Avidity Biosciences Long Term Debt

Track Avidity Biosciences's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
100.00% YoYΔ $-2.09M vs prior year quarter

Peer average / median

Loading

Avidity Biosciences Long Term Debt History

Loading

Avidity Biosciences vs. peers: Long Term Debt Comparison

Loading

Avidity Biosciences Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Avidity Biosciences (RNA) FAQ

As of the most recent data (March 2026), RNA shows a long-term debt of $0. That compares with $2.1M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RNA's long-term debt is now $0 (was $2.1M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Avidity Biosciences is outperforming or lagging.

Tracking RNA's long-term debt over time shows whether Avidity Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $2.1M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Avidity Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Avidity Biosciences's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.